A higher real-life rate of cardiovascular events was assessed in a recent Danish registry in lung cancer or melanoma patients (1-year absolute risk of cardiac events of 9.7% and 6.6% with PD‐1 inhibitors, respectively, and melanoma 7.5% with CTLA‐4 inhibitors) [97]. This evidence concerns the gene CTLA4 and melanoma.